Laboratory Medicine Program

Urothelial/Bladder Carcinoma

Clinical Decription:
Urothelial/ bladder cancer can present as nonmuscle-invasive, muscle-invasive, or metastatic disease. Genetic testing to uncover potential therapeutically targetable mutations is recommended in cases of advanced stage and metastatic disease. The test is performed on tissue to identify patients with urothelial cancer that harbor alterations in the FGFR1, FGFR2, FGFR3 and FGFR4 genes, and are therefore eligible for treatment with FGFR inhibitors.

Method: Next-Generation Sequencing (NGS)

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Paraffin-embedded material (FFPE)/Cytology fluids
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Gene (FGFR1, FGFR2, FGFR3, FGFR4) See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227